Войти в систему Зарегистрироваться бесплатно

ProMIS Neurosciences Валовая прибыль

Что обозначает Валовая прибыль в ProMIS Neurosciences?

Валовая прибыль ProMIS Neurosciences, Inc. является -46,300.00%

Какое определение для Валовая прибыль?



Валовая прибыль - это разница между доходом и стоимостью проданных товаров, разделенная на доход и выраженная в процентах.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Валовая прибыль компаний в Health Care сектор на TSX по сравнению с ProMIS Neurosciences

Что делает ProMIS Neurosciences?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Компании с валовая прибыль похож на ProMIS Neurosciences